A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

Anxiety Disorders Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00543920
• Other study ID #: 0777-020
• Secondary ID: 2007_633
• Status: Completed
• Phase: Phase 2
• First received: October 5, 2007
• Last updated: November 25, 2015
• Start date: August 2002
• Est. completion date: February 2003

Study information

• Verified date: November 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: February 2003
• Est. primary completion date: February 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosis of General Anxiety Order

Exclusion Criteria:

• Women who are pregnant or breast-feeding

• History of severe drug reaction

• History of severe drug withdrawal symptoms such as seizures or delirium

• Disease of cardiovascular system

• Disease of the liver, kidneys, endocrine system, metabolic system or eyes

• History of seizures or seizure disorder

• History of drug or alcohol abuse

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anxiety Disorders

Intervention

Drug:
• MK0777

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.